Significantly reduced tumour growth with new candidate

pharmafile | January 25, 2022 | News story | Manufacturing and Production  

Spago Nanomedical AB announced new clinical and preclinical results for the company’s leading candidate drug, Tumorad® (177Lu-SN201). In a preclinical model for colorectal cancer, the drug was shown to significantly reduce tumour growth and prolong survival.

Together with previously communicated clinical and preclinical results, the new results provide additional support for the company’s unique platform technology with nanoparticles, for use in multiple different cancer indications.

The new results showed that 177Lu-SN201 delays tumour growth, and prolongs survival by 39% in a preclinical model of colorectal cancer, compared to the control group. These results reinforce previous preclinical results with 177Lu-SN201 from a mouse model in aggressive breast cancer.

The clinical needs for new types of cancer treatment is significant. 177Lu-SN201 is being developed as a new type of radionuclide therapy, for the treatment of cancer, where tumours are radiated locally inside the body. Because the material accumulates in fast-growing tumours, the treatment has the potential to reach both aggressive and disseminated tumours.

”We are currently evaluating various alternatives to optimize clinical development and the path to the market. With 177Lu-SN201 we have the opportunity to supplement or combine existing standard treatments, and we see interesting possibilities in both larger indications and rarer, so-called orphan indications”, said Mats Hansen, CEO of Spago Nanomedical.

177Lu-SN201 is considered to be able to treat tumours alone or in synergy with other types of therapies. The project is protected by approved patients in several strategically important regions, including the US, the EU, and Japan.

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumours.

Ana Ovey

Related Content

No items found

Latest content